[The gamma-distribution used for data that is skewed and bounded to the right, i.e. where the maximum of the distribution curve is located near the origin. The g-distribution has a two parameters a and b. The relationship to mean m and variance s2 is m = a b and s2 = a b2. ( HL7V3.0 )] (UMLS (HL7) C1552644) =Intellectual Product =ProbabilityDistributionType;;
[A second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. This agent appears to be less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin. ( NCI )] (UMLS (NCI) C0093999) =Organic Chemical; Pharmacologic Substance
[A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. ( NCI )] (UMLS (NCI) C1513302) Common Terminology Criteria for Adverse Events Grade 1;;CTCAE Grade 1;;Grade 1;;Grade 1 Mild Adverse Event;;MILD;;Mild Adverse Event;;Standard Toxicity Grade 1;; =Finding ;;
[A synthetic derivative of L-arginine with antithrombotic activity. Argatroban is a univalent and direct inhibitor of fibrin-bound thrombin. This agent reversibly binds to the thrombin active site thereby preventing the thrombin-dependent reactions, which include conversion of fibrinogen to fibrin; the activation of factors V, VIII and XI; the activation of protein C; and platelet aggregation. Argatroban is highly selective for thrombin and is able to inhibit the action of both free and clot-associated thrombin. As a result, stabilization of blood clots and coagulation is inhibited. ( NCI )] (UMLS (NCI) C0048470) =Organic Chemical; Pharmacologic Substance =[BL100] ANTICOAGULANTS;;Pipecolic Acids =ARGATROBAN 100 MG/ML